Dual Checkpoint Inhibition in Adjuvant Renal Cell Carcinoma: Phase III Evidence for Durvalumab-Tremelimumab Combination
A phase III randomized controlled trial demonstrates statistically significant improvement in disease-free survival with adjuvant durvalumab plus tremelimumab in resectable renal cell carcinoma. The combination regimen represents a potential paradigm shift in postoperative management of high-risk RCC patients.